JP2012524278A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524278A5
JP2012524278A5 JP2012506186A JP2012506186A JP2012524278A5 JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5 JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012506186 A JP2012506186 A JP 2012506186A JP 2012524278 A5 JP2012524278 A5 JP 2012524278A5
Authority
JP
Japan
Prior art keywords
cancer
histone
h3k18ac
low
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031112 external-priority patent/WO2010120942A2/en
Publication of JP2012524278A publication Critical patent/JP2012524278A/ja
Publication of JP2012524278A5 publication Critical patent/JP2012524278A5/ja
Pending legal-status Critical Current

Links

JP2012506186A 2009-04-14 2010-04-14 がんの臨床診断および予後診断のためのヒストン修飾パターン Pending JP2012524278A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16921609P 2009-04-14 2009-04-14
US16921209P 2009-04-14 2009-04-14
US61/169,216 2009-04-14
US61/169,212 2009-04-14
US22516209P 2009-07-13 2009-07-13
US61/225,162 2009-07-13
PCT/US2010/031112 WO2010120942A2 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Publications (2)

Publication Number Publication Date
JP2012524278A JP2012524278A (ja) 2012-10-11
JP2012524278A5 true JP2012524278A5 (https=) 2013-06-13

Family

ID=42983132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506186A Pending JP2012524278A (ja) 2009-04-14 2010-04-14 がんの臨床診断および予後診断のためのヒストン修飾パターン

Country Status (8)

Country Link
US (1) US20120094949A1 (https=)
EP (1) EP2419737A4 (https=)
JP (1) JP2012524278A (https=)
CN (1) CN102460173A (https=)
AU (1) AU2010236415A1 (https=)
BR (1) BRPI1013546A2 (https=)
CA (1) CA2758933A1 (https=)
WO (1) WO2010120942A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
WO2015102536A1 (en) * 2013-12-30 2015-07-09 Agency For Science, Technology And Research Methods for measuring biomarkers in gastrointestinal cancer
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
AU2015340378B2 (en) * 2014-10-29 2021-08-12 Belgian Volition Sprl Method for the enrichment of circulating tumor DNA
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
CA3033094A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110221072B (zh) * 2019-06-10 2022-08-02 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006B (zh) * 2021-01-28 2022-12-27 中山大学 一种乳腺癌预后预测分子标志物及其应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2024233383A1 (en) * 2023-05-05 2024-11-14 University Of Utah Research Foundation Systems and methods for point-of-care assessment based on pathology image analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ATE489624T1 (de) * 2005-04-29 2010-12-15 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Similar Documents

Publication Publication Date Title
JP2012524278A5 (https=)
Zhou et al. Increased expression of long-noncoding RNA ZFAS1 is associated with epithelial-mesenchymal transition of gastric cancer
Lohaus et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Maráz et al. Thrombocytosis has a negative prognostic value in lung cancer
Chen et al. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
Wang et al. Lymphatic microvessel density and vascular endothelial growth factor-C and-D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature
Zhao et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
Ding et al. HOXB8 promotes tumor metastasis and the epithelial–mesenchymal transition via ZEB2 targets in gastric cancer
Zhang et al. The prognostic value of the preoperative albumin to alkaline phosphatase ratio in patients with non‐small cell lung cancer after surgery
Lu et al. Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival
Dabner et al. Merkel cell Polyomavirus and p63 status in Merkel cell carcinoma by immunohistocnemistry: Merkel cell Polyomavirus positivity is inversely correlated with sun damage, but neither is correlated with outcome
Hu et al. Noninvasive diagnosis of nasopharyngeal carcinoma based on phenotypic profiling of viral and tumor markers on plasma extracellular vesicles
Ge et al. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma
Fiala et al. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib
Martí et al. Prognostic value of serum neutrophil gelatinase‐associated lipocalin in metastatic and nonmetastatic colorectal cancer
Munoz-Colmenero et al. Plasma tumor M2-pyruvate kinase levels in different cancer types
Jouhi et al. The expression of Toll-like receptors 2, 4, 5, 7 and 9 in Merkel cell carcinoma
Alexander et al. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas
Yan et al. Significance of tumour cell HLA‐G5/‐G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients
Marín-Rubio et al. S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma
Ellinger et al. Evaluation of global histone acetylation levels in bladder cancer patients
Heubner et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer
Jessica Mok et al. Is C-reactive protein the single most useful predictor of difficult laparoscopic cholecystectomy or its conversion? A pilot study
Marchi et al. Prognostic significance of peripheral T‐cell subsets in laryngeal squamous cell carcinoma
Salzman et al. Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer